|
|
200 East First Street, Suite 300
Winston-Salem, NC 27101-4165 USA
phone:(336) 480-2100
fax:(336) 480-2107
|
|
| Symbol |
TRGT |
| Exchange |
NASDAQ |
| Founded |
2000 |
| Employees |
|
|
|
| www.targacept.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| A central nervous system focused biopharmaceutical company. |
|
| Management |
| J. Donald deBethizy, Ph.D., President and Chief Executive Officer; Merouane Bencherif, M.D., Ph.D., Vice President, Preclinical Research; Jeffrey P. Brennan, Vice President, Business and Commercial Development; William S. Caldwell, Ph.D., Vice President, Drug Discovery and Development; Geoffrey C. Dunbar, M.D., Vice President, Clinical Development and Regulatory Affairs |
| |
|
|
|
|
|
|
|
| Keywords |
| nicotine, therapeutic, acetylcholine, inflammation, schizophrenia |
|
|
|
| Description |
|
it is a central nervous system focused company with a portfolio of therapeutic candidates. The Company is developing anew class of drugs that selectively modulate a class of molecular targets called neuronal nicotinic receptors ("NNRs") which are involved in regulating the nervous system's activity. |
|
| Products / Services |
Targacept currently has one product on the market, Inversine, for the management of hypertension, and has multiple product candidates in development for treating various disorders, including memory and dementia (Phase II), attention deficit hyperactivity disorder (Phase II), ulcerative colitis (Phase II) and pain (Phase I). Targacept also has preclinical candidates for Alzheimer's diseases, depression/anxiety, schizophrenia, and smoking cessation, as well as discovery programs in obesity, Parkinsons' and inflammation.
|
|
| Technology / Differentiation |
| The company's proprietary in-silico drug discovery engine enable the identification of drug candidates that target specific receptors that provide therapeutic benefit with limited side effects |
|
|
| Status |
| Targacept secured $30.4 million in its first round of venture capital financing to advance its research and development pipeline, and in 2003 completed a $60 million financing from top-tier science investors, further supporting the advancement and expansion of the company's product portfolio. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
